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Abstract
Background: The envelope (E) protein of dengue virus (DENV) is the major target of neutralizing antibodies and vaccine
development. While previous studies on domain III or domain I/II alone have reported several epitopes of monoclonal
antibodies (mAbs) against DENV E protein, the possibility of interdomain epitopes and the relationship between epitopes
and neutralizing potency remain largely unexplored.
Methodology/Principal Findings: We developed a dot blot assay by using 67 alanine mutants of predicted surface-exposed
E residues as a systematic approach to identify epitopes recognized by mAbs and polyclonal sera, and confirmed our
findings using a capture-ELISA assay. Of the 12 mouse mAbs tested, three recognized a novel epitope involving residues
(Q211, D215, P217) at the central interface of domain II, and three recognized residues at both domain III and the lateral
ridge of domain II, suggesting a more frequent presence of interdomain epitopes than previously appreciated. Compared
with mAbs generated by traditional protocols, the potent neutralizing mAbs generated by a new protocol recognized
multiple residues in A strand or residues in C strand/CC9 loop of DENV2 and DENV1, and multiple residues in BC loop and
residues in DE loop, EF loop/F strand or G strand of DENV1. The predominant epitopes of anti-E antibodies in polyclonal sera
were found to include both fusion loop and non-fusion residues in the same or adjacent monomer.
Conclusions/Significance: Our analyses have implications for epitope-specific diagnostics and epitope-based dengue
vaccines. This high throughput method has tremendous application for mapping both intra and interdomain epitopes
recognized by human mAbs and polyclonal sera, which would further our understanding of humoral immune responses to
DENV at the epitope level.
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Introduction
Dengue virus (DENV) belongs to the genus Flavivirus in the
family Flaviviridae. The four DENV serotypes (DENV1, DENV2,
DENV3, and DENV4) are the leading cause of arboviral diseases
in the tropical and subtropical areas [1,2]. It has been estimated
that more than 2.5 billion people in over 100 countries are at risk
of infection and more than 50 million dengue infections occur
annually worldwide [1,2]. The clinical presentations after DENV
infection range from asymptomatic infection or a self-limited
illness, dengue fever (DF), to severe and potentially life-threatening
diseases, dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS) [1,2]. Despite the development of candidate vaccines,
several being tested in clinical trials, there is no dengue vaccine
currently available [3].
DENV contains a positive-sense, single-stranded RNA genome
of about 10.6 kilobases in length. Flanked by the 59 and 39
untranslated regions, the genome has a single open reading frame
encoding a polyprotein precursor, which is cleaved by cellular and
viral protease into three structural proteins, the capsid, precursor
membrane (prM) and envelope (E), and seven non-structural
proteins [4]. DENV enters the cell via receptor-mediated
endocytosis [4–6]. Within the endosome, a series of E protein
conformational changes is triggered by low pH, leading to the
fusion of viral membrane to endosomal membrane [5,7].
Following uncoating, translation and RNA replication, assembly
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virions transport through the ER lumen to the secretory pathway
[4,5,8,9]. In the trans-Golgi, mature virions are produced after
prM protein is cleaved by furin or furin-like protease, though the
cleavage is often inefficient [10–13]. During flaviviral replication,
small and slowly-sedimenting subviral particles are produced [4].
Expression of prM and E proteins together can produce
recombinant virus-like particles (VLPs). The E proteins on VLPs,
which had a different symmetry, were reported to be structurally
and antigenically similar to those on infectious virions [14–16].
VLPs have been used as non-infectious serodiagnostic reagents
and flavivirus vaccine candidates [17–20].
The E protein forms 90 ‘‘head to tail’’ homodimers on the
surface of mature virions [4,5,21]. E protein participates in virus
entry and is the major target of neutralizing antibodies (Abs),
which correlate with the protection against infection [4,22]. In the
presence of some cross-reactive non-neutralizing anti-E Ab,
DENV replicates to higher titers in human monocytes in vitro,a
phenomenon known as antibody-dependent enhancement (ADE)
[23], suggesting that E protein is also the target of enhancing Abs.
X-ray crystallographic studies of the ecotodomain of E protein
reveals three distinct domains [7,24]. Domain I is located at the
center. Domain II contains an internal fusion loop at the tip and is
involved in membrane fusion and dimerization of E protein.
Domain III is believed to participate in receptor binding [4,5,25].
In the genus Flavivirus, there are clusters of mosquito- and tick-
borne viruses. The mosquito-borne viruses consist of the Japanese-
encephalitis virus (JEV) serocomplex including JEV, West Nile
virus (WNV), St. Louis encephalitis virus (SLEV), Murray Valley
encephalitis virus (MVEV) and Kunjun virus (KUNV), the DENV
serocomplex including four serotypes of DENV, and the yellow
fever virus (YFV) as a single member. Among the tick-borne
viruses are the tick-borne encephalitis virus (TBEV) serocomplex,
including central European, Far Eastern and Powassan TBEV [4].
Anti-E Abs that recognize members from different serocomplexes,
all/subset of members within a serocomplex and a single member
are called flavivirus group-reactive (GR), complex/subcomplex-
reactive (CR/sCR) and type-specific (TS), respectively [26].
Previous studies of mouse anti-E monoclonal antibodies (mAbs)
against DENV reported that the epitopes of GR mAbs were
primarily mapped to highly conserved residues at the fusion loop
of domain II [27,28]. Using a yeast surface-display library
containing domain III or domain I/II alone or recombinant
domain III, the epitopes of CR/sCR mAbs were mapped to
domain III, whereas those of TS mAbs were also mapped to
domain III [29–35]. However, several questions regarding the
epitopes on DENV E protein remain largely unknown. A recent
study revealed that potent neutralizing mAbs against JEV derived
from Fabs of chimpanzees recognized residues in domain I or
domain II plus those in domain III, suggesting the presence of
interdomain epitope [36]. Similarly, two potent human mAbs
against WNV E protein were reported to recognize residues at
domain II dimer interface and domain I/II hinge region [37]. The
possibility of interdomain epitopes on DENV E protein, which
cannot be identified by systems using recombinant domain I/II or
III alone, remains to be investigated. Additionally, the neutralizing
potency of the recently reported anti-E mAbs, which were
generated by a novel immunization protocol involving IFN-a/b
R -/- C57BL/6 mice [33–35], was much higher than previously
described mAbs [29,30,32,38–42]. Whether the epitope residues
recognized by these potent neutralizing mAbs differ from those
recognized by less potent neutralizing mAbs remains unclear.
In this study, we generated a panel of 67 alanine-substitution
mutants covering the predicted surface-exposed E residues on a
DENV1 prM/E expression construct as a systematic approach to
investigate the epitopes on different domains of E protein
recognized by mouse mAbs and polyclonal human sera. The
identified epitopes were further verified by capture-ELISA using
VLPs. Moreover, analysis of the epitopes of the potent neutralizing
mAbs in comparison with those of less the potent neutralizing
mAbs provided new insights for future strategies of epitope-based
dengue vaccine.
Materials and Methods
Mouse mAbs
The mouse anti-E mAbs studied included five GR mAbs
(FL0232, FL0231, 4G2, DEN2-12 and DEN4-4), four DENV
CR/sCR mAbs (DEN2-9, DEN3-3, DEN3-4 and DEN1-2), and
three DENV1 TS mAbs (FL0251, DA6-7 and DEN1-3). FL0232,
FL0231 and FL0251 were purchased from Chance Biotechnology
(Taipei, Taiwan), and 4G2 from American type culture collection
(Rockville, MD). Other mAbs were generated by immunization of
BALB/c mice with DENV1 (DEN1-2, DA6-7 and DEN1-3),
DENV2 (DEN2-12, DEN2-9), DENV3 (DEN3-3, DEN3-4) or
DENV4 (DEN4-4) as described previously [38].
Ethics Statement and Human Sera
With the approval of the Institutional Review Board of the
University of Hawaii at Manoa (CHS#17568) and National
Taiwan University (IRB#1003701987), convalescent sera of
confirmed dengue patients from the Kaohsiung Medical Univer-
sity Hospital between 2002 and 2009 and from the Center for
Disease Control Taiwan were included in the analysis of Abs
response to DENV. Informed consent was obtained, and all
samples were coded for anonymity. WHO case definitions were
used to diagnosed DF and DHF [2]. Primary or secondary
infection was confirmed by plaque reduction neutralizing test
(PRNT) (see below). Primary infection was defined by monotypic
neutralization pattern with PRNT50 $20 to only one serotype or
$20 to multiple serotypes with PRNT50$80 to only one serotype
[43,44]. Secondary infection was defined by PRNT50$20 to
Author Summary
Dengue virus is the leading cause of arboviral diseases
worldwide. The envelope protein is the major target of
neutralizing antibodies and vaccine development. While
previous studies have reported several epitopes on
envelope protein, the possibility of interdomain epitopes
and the relationship of epitopes to neutralizing potency
remain unexplored. We developed a high throughput dot
blot assay by using 67 alanine mutants of surface-exposed
envelope residues as a systematic approach to identify
epitopes recognized by mouse monoclonal antibodies and
polyclonal human sera. Our results suggested the presence
of interdomain epitopes more frequent than previously
appreciated. Compared with monoclonal antibodies gen-
erated by traditional protocol, the potent neutralizing
monoclonal antibodies generated by a new protocol
showed several unique features of their epitopes. More-
over, the predominant epitopes of antibodies against
envelope protein in polyclonal sera can be identified by
this assay. These findings have implications for future
development of epitope-specific diagnostics and epitope-
based dengue vaccine, and add to our understanding of
humoral immune responses to dengue virus at the epitope
level.
Epitope Analysis of Anti-DENV Envelope Antibodies
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ELISA was used to exclude recent JEV infection [44].
Plasmid and E Mutant Constructs
The plasmid expressing prM/E proteins of DENV1 (Hawaii
strain), pCB-D1, was described previously [45]. To generate E
mutant constructs, site-directed mutagenesis was performed by
using pCB-D1 as template and single-step PCR mutagenesis to
replace each of the selected E residues with an alanine [46]. Sixty
E residues predicted to be surface-exposed as well as seven domain
III E residues previously reported as epitopes of several mAbs were
chosen for mutagenesis [29-35,47]. All mutant constructs were
confirmed by sequencing the entire insert to rule out second site
mutation. The sequences of all PCR primers will be provided
upon request.
Transfection and Western Blot Analysis
293T cells (1610
5 cells) were transfected with 10 mg of each
plasmid DNA by calcium phosphate method. At 48 h, cells were
washed with 16 PBS and lysed with 1% NP40 lysis buffer
(100 mM Tris [pH 7.5], 150 mM NaCl, 20 mM EDTA, 1%
NP40, 0.5% Na deoxycholate) containing protease inhibitors
(Roche Diagnostics), followed by centrifugation at 20,0006ga t
4uC for 30 min to obtain cell lystates [44]. Aliquots of cell lysates
were added to non-reducing buffer (2% SDS, 0.5 M Tris
[pH 6.8], 20% glycerol, 0.001% bromophenol blue [final
concentration]) and subjected to 12% polyacrylamide gel
electrophoresis (PAGE) and Western blot analysis [44]. The first
Ab included mixed human sera consisting of a pool of 9 sera from
dengue patients with secondary infection and each mAb. Cell
lysates were also collected from C6/36 cells infected with mock,
DENV1 (Hawaii strain), DENV2 (NGC strain), DENV3 (H87
strain), DENV4 (H241 strain), JEV (RP-9 strain) or WNV (NY99
strain), and subjected to 12% PAGE and Western blot analysis
with each mAb to determine the binding specificity. Verification of
similar amounts of antigen loading was done by Western blot
analysis using mixed human sera, as described previously [44].
Dot Blot Assay
Aliquots of cell lysates (in 1% NP40 lysis buffer) derived from
the above transfectants were diluted in bromophenol blue
containing 16 PBS and dot blotted by using a 96-dot formatted
dot-blotter (Labrepco) to nitrocellulose membrane (Hybond-C;
Amersham Biosciences). After blocking of the membrane with 4%
milk in wash buffer, incubation with the first Ab (mixed mAbs
consisting a pool of mAbs recognizing different epitopes, each
mAbs or serum) and secondary Ab (horseradish peroxidase-
conjugated anti-human or anti-mouse IgG) (Pierce), and final
washing, the signals were detected by enhanced chemilumines-
cence reagents (Perkin Elmer life sciences) [44]. The intensities of
E protein dots (dot blot assay) or bands (Western blot analysis) of
wild type (WT) pCB-D1 and mutants were analyzed by
imageQant (GE Healthcare, UK) [44]. The recognition index
(R.I.) of a mAb to a mutant E protein was calculated as previously
described [44,48]. Briefly, R.I.=[intensity of mutant E dot (or
band)/intensity of WT E dot (or band)] (recognized by a mAb)/
[intensity of mutant E dot (or band)/intensity of WT E dot (or
band)] (recognized by mixed mAbs or mixed sera).
VLP-Capture ELISA
293T cells (1610
5 cells) were transfected with 10 mg of plasmid
DNA as described above. At 48 h, culture supernatants were
collected, clarified by centrifugation at 1,2506g for 20 min,
filtered through a 0.22 mm pore-sized membrane (Sartorius),
layered over a 20% sucrose buffer, and ultracentrifuged at
65,0006ga t4 uC for 5 h to obtain pellets containing VLPs, which
were resuspended in 30 ml TNE buffer [45]. Flat-bottom 96 well
plate was coated with rabbit anti-sera against DENV1 at 4uC
overnight, followed by blocking with 1% BSA in 16PBS for 1 h.
VLPs and mutant VLPs (at about 0.1 mg/ml, as determined by
SDS-12% PAGE and Coomassie blue staining with BSA of known
concentration as standards), serially two-fold dilutions of purified
anti-E mAb, and anti-mouse IgG conjugated with HRP were
added each at 37uC for 1 h, followed by TMB substrate and stop
solution [27,28]. Comparable amounts of WT and mutant VLPs
added were confirmed by mixed mAbs, and the absorbance at
wavelength of 450 nm (OD450) with reference wavelength of
650 nm was read. Binding curves, maximum binding (Bmax) and
relative binding (% of Bmax) were determined by a nonlinear
regression analysis with GraphPad Prism5 (GraphPad software
Inc., CA).
PRNT
Each anti-E mAb was purified by Protein G HP Spin Trap kit
(GE Healthcare). Serially two-fold dilutions of purified anti-E mAb
were mixed with 50 plaque forming unit (pfu) of DENV1 (Hawaii
strain) at 37uC for 1 h, followed by inoculation to BHK-21 cells in
24-well plate (in duplicates) at 37uC for 2 h, overlay with MEM
containing 2% FBS, antibiotic and 1% carboxymethyl cellulose)
and incubation at 37uC for 5 to 7 days [38]. Cells were stained
with 0.5% crystal violet; the plaques were counted and PRNT50
was presented as the lowest concentration that inhibited $50% of
plaques.
Epitope Analysis by Structure-Based Modeling
The program FirstGlance in Jmol version 1.44 (http://molvis.
sdsc. edu/fgij/index.htm) was used to determine the locations of
candidate epitope residues and distances between them (at the
same or adjacent monomer) on E-E dimers. Similar analysis was
also carried out by using the program UCSF chimera (http://
www.cgl.ucsf.edu/chimera/) for E protein on the virus particles.
Results
Evaluation of the Binding Specificity of Multiple Anti-E
mAbs to Flaviviruses
First, the binding specificity of 12 mouse anti-E mAbs was
investigated by Western blot analysis using cell lysates derived
from C6/36 cells infected by each of the 4 serotypes of DENV and
JEV. MAbs DEN2-12, FL0232, FL0231, 4G2 and DEN4-4
recognized the E proteins of DENV1 to DENV4 and JEV,
suggesting that they were flavivirus GR mAbs (Figure 1B and
Figure S1). MAbs DEN2-9 and DEN3-3 recognized the E proteins
of 4 DENV serotypes but not that of JEV, suggesting that they
were CR mAbs, whereas mAbs DEN3-4 and DEN1-2 recognized
the E proteins of DENV1 to DENV3, suggesting that they were
sCR mAbs (Figure S1). MAbs DA6-7, DEN1-3 and FL0251
recognized DENV1 E protein only, suggesting that they were
DENV1 TS mAbs.
Epitope Mapping of Flavivirus GR and CR mAbs
To identify the epitopes recognized by these anti-E mAbs, site-
directed mutagenesis was performed on a DENV1 prM/E
expression construct, pCB-D1, to replace each of the 67 E
residues, which were predicted to be surface-exposed or previously
reported as epitopes of several mAbs, with an alanine [45,48].
Since these mAbs recognized E protein only without significant
Epitope Analysis of Anti-DENV Envelope Antibodies
www.plosntds.org 3 January 2012 | Volume 6 | Issue 1 | e1447Figure 1. Specificity and epitope of flavivirus GR mAb DEN2-12. (A) Layout of the dot blot assay. (B) Binding specificity was examined by
Western blot analysis as described in Methods. Lysates of 293T cells transfected with pCB-D1 (D1 tr) were also included. (C) Dot blot assay using
lysates from 293T cells transfected with the WT pCB-D1 or each of the 67 alanine E mutants. Each membrane was probed with mAb DEN2-12 or
mixed mAbs (a pool of mAbs recognizing different epitopes). The dots containing mutations in domains I, II and III are underlined by red, yellow and
blue lines, respectively; the ID of each dot is shown in panel A. Two-fold dilutions of the WT lysates were dotted on row 1 to assess the exposure of
each membrane. Arrows indicate mutants of epitope residues, which showed severe reduction (R.I.#0.3) in binding by dot blot assay. One
representative experiment of two was shown. (D) The relative intensities of WT dots in row 1 showed a linear decrease from 16to 1:16 dilution for
membranes probed with mixed mAbs (open bar) and mAb DEN2-12 (closed bar). (E) The intensities of each dot were quantified to determine the R.I.
as described in Methods. Data are means and standard errors of two experiments. (F) Capture ELISA was performed by using WT or mutant VLPs [28],
which had severe reduction in binding by dot blot and Western blot analyses. Data are means and standard errors of duplicates from one
representative experiment of two. Lower graph shows the amounts of mutant VLPs added, which were not less than that of WT. (G) Structure-based
analysis by UCSF chimera program to determine the locations of and distance (uA) between epitope residues from the same (shaded) or adjacent
monomer.
doi:10.1371/journal.pntd.0001447.g001
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mapping by blotting cell lysates derived from transfectants of each
mutant in a 96-dot format, hybridized with each mAb or a pool of
mixed mAbs, and examined the residues with loss of binding. To
exclude the possibility of over-exposure, we dotted each mem-
brane with two-fold serial dilutions of WT lysates; each membrane
showed a linear decrease in intensity (Figure 1D). The intensity of
each mutant dot recognized by mixed mAbs was generally
comparable to that of the WT dot, suggesting that comparable
amounts of E protein were dotted in the membrane (Figure 1C).
Compared with that of the WT, the E binding activity of DEN2-
12 was greatly reduced by two alanine mutants at the fusion loop
of domain II (W101A and F108A) but not by other mutants,
suggesting that these two residues were possibly the epitope of
DEN2-12. We also calculated the R.I., which was the ratio of the
intensity of the mutant E dot to that of WT dot recognized by a
mAb divided by such ratio recognized by mixed mAbs [44,48],
and found a great reduction in R.I. for mutants W101A and
F108A (Figure 1E). The results were further verified by Western
blot analysis (Figure S2A). To further examine the binding of
DEN2-12 to mutants W101A and F108A in the context of
particles, we employed a previously described capture ELISA
using WT and mutant VLPs [27,28]. While DEN2-12 bound to
mutant VLPs of L107A comparably to its binding to WT VLPs, it
bound poorly to mutant VLPs of W101A or F108A (Figure 1F).
Analysis of the locations of these residues by a structure-based
modeling program revealed that the distance between these two
residues from the same monomers was less than 30uA (Figure 1G),
suggesting that residues W101 and F108 very likely constitute the
epitope of DEN2-12.
By using the same approach, the epitopes of the other three GR
mAbs (FL0232, FL0231 and 4G2) were found to involve four
fusion loop residues (W101A, G106A, L107A and F108A) with
different combinations (Table 1). For another GR mAbs (DEN4-
4), dot blot assay revealed that the E-binding activity was greatly
reduced by three mutants (Q211A, D215A and P217A) at the
central interface of domain II but not by fusion loop mutants
(Figures 2A to 2C); this was further confirmed by Western blot
analysis (Figure S2B) and VLP-capture ELISA (Figure 2D).
Structure-based analysis revealed that the distances between these
residues from the same or adjacent monomers were less than
30uA, suggesting that these three residues likely form an
interdomain epitope at the domain II central interface
(Figure 2E). This is a novel epitope for GR mAbs, since all the
GR mAbs reported thus far were mainly mapped to the fusion
loop [27,28]. Interestingly, two CR mAbs were also found to have
an interdomain epitope at the domain II central interface,
including residues P217 and T265 for DEN2-9 and residue
P217 for DEN3-3 (Table 1).
Epitope Mapping of sCR and TS mAbs
For the TS mAb FL0251, four epitope residues were identified,
including severe reduction in binding (R.I.#0.3) of 3 mutants at
the A strand (K307A, K310A) and G strand (L389A) of domain III
and moderate reduction in binding (0.3,R.I.#0.5) of a mutant at
the lateral ridge (V83A) of domain II (Figures S3A to S3D).
Mutants F373A and W391A, which showed severe and moderate
reduction in binding by dot blot assay, respectively, were excluded
as epitope residues by VLP-capture ELISA (Figure S3D). This is
probably related to different accessibility of these two residues in E
protein solublized by NP40 lysis buffer and in the context of
particles. Structure-based analysis revealed that the distances
between the three domain III residues from the same monomer as
well as those between domain III residue (K310) and domain II
residue (V83) from the adjacent monomer were less than 30uA,
suggesting an interdomain epitope (Figure S3E).
Similarly, the epitopes of another TS mAb (DEN1-3) and a sCR
mAb (DEN3-4) were interdomain epitopes involving residues at
domain III and domain II lateral ridge (Table 1). The epitopes of
another TS mAb (DA6-7) and a sCR mAb (DEN1-2) were found
to involve domain III residues only (Table 1).
Relationship between Neutralizing Potency and Epitope
We next examined the neutralizing potency of these 12 mAbs.
In agreement with previous reports, the neutralizing potency of TS
or sCR mAbs was generally greater than that of CR or GR mAbs
(Table 1) [29,30,32]. However, the neutralizing potency of our TS
or sCR mAbs (PRNT50 in the range of mg/ml) was much lower
than that of the potent TS or sCR mAbs reported recently
(PRNT50 in the range of ng/ml) [33–35]. It is worth noting that
these potent neutralizing mAbs were generated by a novel
immunization protocol involving two DENV challenges in IFN-
a/b R -/- C57BL/6 mice and a booster with recombinant domain
III, whereas previous protocols (including ours) involved immu-
nization of WT BALB/c mice with DENV [29,30,32,38–42]. To
investigate if these potent neutralizing mAbs recognize epitopes
different from those recognized by less potent mAbs, we compared
the epitopes and PRNT50 of mAbs generated from two different
protocols using DENV1 or DENV2 as immunogen (Table S1).
For the mAbs against DENV2, both groups recognized residues in
the A strand, BC loop and G strand of domain III (Table 2).
Interestingly, the potent neutralizing mAbs (PRNT50#311 ng/ml)
recognized either four or more residues in the A strand, residues in
the C strand/CC9 loop, or multiple residues in both A strand and
BC loop [34], whereas less potent mAbs commonly recognized
residues in the FG loop [29,32]. Since the epitopes of most of these
DENV2 mAbs were identified by the same assay, it is unlikely that
the epitopes identified were biased by the methods utilized [32,34].
For the mAbs against DENV1, the potent neutralizing mAbs
(PRNT50#590 ng/ml) recognized four residues in the A strand,
three or more than three residues in BC loop, residues in C
strand/CC9 loop, DE loop, EF loop/F strand, or G strand only
[33] (Table 2).
Predominant Epitopes in Polyclonal Human Sera
To further explore the possibility that this assay can be
employed to investigate the predominant epitope of anti-E Abs
in polyclonal human sera, we examined serum from a confirmed
DENV1 secondary infection case. As shown in Figure 3A, Western
blot analysis revealed that this serum can recognize not only the E
protein of DENV1 but also that of DENV2, 3, 4 and WNV. Since
this serum recognized E protein without significant background,
we used the same serum dilution in the dot blot assay. Compared
with that of the WT, the E binding activity was greatly reduced by
two alanine mutants at the fusion loop (W101A and F108A) but
not by other mutants, suggesting that these two residues possibly
constitute a predominant epiotpe in this polyclonal serum
(Figure 3B). This was further verified by VLP-capture ELISA
(Figure 3C). Analysis of the sera from other two cases of secondary
infection by DENV2 (Figures S4A to S4C) or DENV3 (Figures
S4D to S4F) revealed that the E binding activity was severely
reduced by mutants W101A and F108A in both dot blot assay and
VLP-capture ELISA, suggesting that fusion loop residues form a
predominant epitope in these two polyclonal sera. For the DENV2
case, moderate reduction in binding was also found in mutants
T293A at domain I and V122A at domain II. Table 3 summarizes
the results of 14 secondary infection cases including six DENV1
cases, three DENV2 cases and five DENV3 cases. The E binding
Epitope Analysis of Anti-DENV Envelope Antibodies
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fusion loop including W101A and F108A and/or L107A and
G106A, suggesting these are the predominant epitopes. Interest-
ingly, the E binding activities were also moderately affected by
some mutations outside of the fusion loop such as G78A, V122A,
D290A and T293A. The distance between fusion loop residues
and residue G78 of the same monomer was less than 30uA and
that between fusion loop residues and D290 or T293 from the
adjacent monomer was close to 30uA, suggesting that they likely
form a predominant epitope.
Discussion
In this study we developed a high throughput dot blot assay to
investigate the epitopes on E protein recognized by mouse mAbs
and polyclonal human sera; the epitope residues were further
verified by a VLP-capture ELISA assay to ensure accurate epitope
mapping. Of the 12 mAbs studied, three mAbs recognized a novel
epitope involving residues at the domain II central interface
(residues Q211, D215D, P217) and three mAbs recognized
residues at both domain III and the lateral ridge of domain II,
suggesting a more frequent presence of interdomain epitopes than
previously appreciated. Identification of such epitopes on the
virion surface typically requires a cryo-EM study of virions in the
presence of Fab of mAb, as recently demonstrated by the study of
a human mAb (CR4354) spanning domains III and I of adjacent E
monomers on WNV virions [49]. Compared with the epitopes of
mAbs generated by traditional protocols, the epitopes of potent
neutralizing mAbs generated by a new protocol involving IFN-a/b
R -/- C57BL/6 mice showed several interesting and unique
features (Table 2). Together, these findings have implications for
Table 1. Summary of the specificity, binding to alanine E mutants and PRNT50 of 12 mAbs.
mAbs Class
* (Specificity) Binding
** Domain II
{
Lateral ridge fusion loop central interface
V83A Q86A W101A G106A L107A F108A Q211A D215A P217A T265A
DEN2-12 GR (DENV1,2,3,4,JEV) dot blot WB ++ ++ ++ ++
FL0232 GR (DENV1,2,3,4,JEV) dot blot WB ++ ++ ++ ++
FL0231 GR (DENV1,2,3,4,JEV) dot blot WB ++ ++ ++ ++ ++ ++
4G2 GR (DENV1,2,3,4,JEV) dot blot WB ++ ++ ++ ++ ++ ++ ++ ++
DEN4-4 GR (DENV1,2,3,4,JEV) dot blot WB ++ ++ ++ ++ + ++
DEN2-9 CR (DENV1,2,3,4) dot blot WB ++ ++ ++ ++
DEN3-3 CR (DENV1,2,3,4) dot blot WB + +
DEN3-4 sCR (DENV1,2,3) dot blot WB ++ ++
DEN1-2 sCR (DENV1,2,3) dot blot WB
FL0251 TS (DENV1) dot blot WB ++
DEN1-3 TS (DENV1) dot blot WB ++
DA6-7 TS (DENV1) dot blot WB
Domain III
{ PRNT50
{
N-terminus A strand BC loop FG loop G strand (mg/ml)
V300A M301A T303A K307A K310A E311A V312A T329A G383A K385A L389A W391A
,6.25
,12.5
.100
,25
,50
,50
,12.5
++ + + +++ ++ ++ ,1.56
++ ++ ++ ++ ++ ++ ++ ++ ++ + ,1.25
++ ++ ++ ++ ++ + ,6.25
++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + + ,0.78
++ ++ ++ ++ + + ++ ++ ++ ++ ,1.25
*Classes of mAbs include GR (group-reactive), CR (complex-reactive), sCR (subcomplex-reactive) and TS (type-specific). Specificity was determined by Western blot (WB)
analysis using lysates derived form DENV1, 2, 3, 4 or JEV-infected C6/36 cells as described in Methods.
**Alanine E mutants with consistent reduction in binding by dot blot and WB analyses are shown. ++: severe reduction in binding (reduction in R.I.$70%);
+: moderate reduction in binding (50%#reduction in R.I.,70%); underlined: reduced binding tested by VLP-capture ELISA.
{Different regions (strand, loop, etc.) of domains II and III are defined based on the X-ray structure of DENV E protein [7,24,33].
{PRNT50 was presented as the lowest concentration that inhibited $50% of plaques [38].
doi:10.1371/journal.pntd.0001447.t001
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based dengue vaccine.
Previous studies of epitope mapping were primarily based on
either yeast surface-display library containing domain III or
domain I/II alone or bacterially expressed recombinant domain
III; the possibility of interdomain epitopes on DENV E protein
cannot be identified by either system [29,30,32–35]. In the
bacterial expression system, fusion proteins containing maltose
binding protein and WT or mutant domain III were coated on
ELISA plate under alkaline buffer (pH 9.0) [29–30], raising the
Figure 2. Epitope mapping of GR mAb DEN4-4. The results of (A, B, C) dot blot assay, (D) VLP-capture ELISA, and (E) structure based analysis of
the locations of and distance (uA) between epitope residues from the same or adjacent monomer are presented as in Figure 1.
doi:10.1371/journal.pntd.0001447.g002
Table 2. Comparison of epitopes and neutralization potency of mAbs recognizing domain III of DENV E protein.
Potent neutralizing mAbs
* Less potent neutralizing mAbs
*
DENV2 as immunogen
Common features residues in A strand, BC loop and G strand residues in A strand, BC loop and G strand
Unique features $4 residues in A strand (such as residues 303, 305, 307, 309) residues in FG loop
residues in C strand/CC9 loop (such as residues 336, 340, 346)
multiple residues in both A strand and BC loop
DENV1 as immunogen
Common features residues in N-terminus, A strand, BC loop and G strand residues in N-terminus, A strand, BC loop and G strand
Unique features 4 residues in A strand (such as residues 303, 305, 307, 309)
residues in C strand/CC9 loop (such as residues 334, 343)
$3 residues in BC loop (such as residues 328, 329, 330, 332)
residues in DE loop (such as residues 361, 362, 364), EF loop/F strand
(such as residues 370, 375), or G strand only (such as residues 390, 391)
*Potent neutralizing mAbs against DENV2 and DENV1 were defined by PRNT50 #311 mg/ml and #590 mg/ml, respectively. Most of the potent neutralizing mAbs were
generated by immunization of IFN-a/b R -/- C57BL/6 mice with DENV twice and booster with recombinant domain III [33,34] , whereas most of the less potent
neutralizing mAbs were generated by immunization of WT BALB/c mice [29,30,32,38–42].
doi:10.1371/journal.pntd.0001447.t002
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The yeast surface-display system involving screening for mutant
library by flow cytometry required a time-consuming process of
sorting, sequencing and confirmation [32–35]. In a newly adopted
dot blot assay, we prepared 67 alanine-substitution mutants in 1%
NP40 lysis buffer without SDS or boiling, a condition similar to
RIPA lysis buffer containing non-ionic detergent to preserve the
conformation of membrane protein, and dotted in the 96-dot
format. A linear decrease in the intensity of two-fold serial
dilutions of WT lysate dots on each membrane suggested that the
assay signal is sensitive to the serial decrease in the amount of E
protein and excluded the possibility of over-exposure. Moreover,
the epitope residues identified were verified by VLP-capture
ELISA to assess the binding in the context of particles; both assays
Figure 3. Binding specificity and predominant epitope recognized by anti-E Abs in serum from a DENV1 case. (A) Binding specificity
was examined by Western blot analysis as described in Methods. Lysates of 293T cells transfected with pCB-D1 (D1 tr) were also included. (B) Dot blot
assay presented as in Figure 1A and 1C to 1E (except that WT dot in row 8C and 153NA dot in row 2H were omitted) was probed with the tested
serum or mixed sera, which consisted of a pool of 9 sera from confirmed dengue patients [44]. The relative intensities of two-fold dilutions of WT dots
in row 1 were presented as in Figure 1D. R.I. of each mutant was shown as in Figure 1E. One representative experiment of two was shown. (C) Capture
ELISA using WT or mutant VLPs was presented as in Figure 1F. Upper graph in panel C shows comparable amounts of WT and mutant VLPs added.
doi:10.1371/journal.pntd.0001447.g003
Table 3. Summary of predominant epitopes recognized by anti-E Abs in human sera after DENV infection.
Patient ID Serotype and immune status
* Disease
** Sampling time (after onset) Predominant epitopes
{ recognized by anti-E Abs
854 Secondary DENV1 DF 19 d W101, F108
895 Secondary DENV1 DF 35 d W101, F108
436 Secondary DENV1 DF 18 d W101, F108
774 Secondary DENV1 DF 45 d W101, (L107)
923 Secondary DENV1 DF 34 d W101, F108 (L107)
27-3 Secondary DENV1 DF 3 months W101, F108 (L107)
45 Secondary DENV2 DF 6 years W101, F108, (V122, T293)
80 Secondary DENV2 DF 6 years (F108)
97 Secondary DENV2 DF 6 years (W101)
92 Secondary DENV3 DF 2 years (W101, F108)
102 Secondary DENV3 DF 6 years W101, F108
70 Secondary DENV3 DF 1.5 years W101, F108
87 Secondary DENV3 DF 2 years F108, (W101, G78, D290)
95 Secondary DENV3 DF 1.5 years W101, F108, (L107, V122)
*Primary or secondary infection was determined by PRNT50 as described in Methods.
**DF, dengue fever according to WHO case definition [2].
{Predominant epitopes recognized by anti-E Abs in polyclonal human sera were identified by dot blot assay and residues with severe (reduction in R.I.$70%) or
moderate (50%#reduction in R.I.,70%, shown in parenthesis) impairment in binding were shown.
doi:10.1371/journal.pntd.0001447.t003
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www.plosntds.org 8 January 2012 | Volume 6 | Issue 1 | e1447Figure 4. Location of epitope residues on E protein recognized by potent neutralizing mAbs. Epitope residues of mAbs against DENV1
(A) and DENV2 (B). Epitope residues are highlighted with dark blue (DENV1 residues), purple (DENV2 residues), or magenta (DENV1 and DENV2
residues at the same position). Top view of E-E dimers (upper) and side view of domain III (lower right) with ribbon presentation of ß-strands and
loops (lower left) are shown by the program UCSF chimera.
doi:10.1371/journal.pntd.0001447.g004
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that since some partially occluded epitopes were shown to be
exposed after conformational movement of E protein [50], certain
interesting and potentially important epitope residues might not be
represented by this panel of 67 residues. Nonetheless, our dot blot
assay is a convenient and high throughput method to investigate
both intra and interdomain epitopes on DENV E protein and has
tremendous applications. Using this approach to study mAbs, our
findings that interdomain epitopes were more frequent than
previously appreciated suggest that subunit vaccines containing
recombinant domain III or domain I/II alone are probably not
optimal to induce neutralizing Abs compared with immunogen
containing entire E protein. Consistent with this interpretation, a
recent study of different subunit vaccine candidates for WNV
revealed that domain III alone elicited at least 15-fold lower
neutralizing activity compared with inactivated virion [51].
Recent studies of polyclonal human sera and mAbs derived from
dengue cases revealed that anti-E Abs were highly cross-reactive
[28,44,52–54]. Studies of human sera by the approach of loss-of-
binding to variant E protein containing mutations in selected
residues in the domain II or domain III reported that a significant
proportion of anti-E Abs after DENV infection recognized the
fusion loop of domain II, whereas only a minor proportion
recognized domain III [28,44]. A similar trend was also observed in
the studies of human sera [55] and mAbs repertoire after WNV
infection [56]. However, a systematic approach was lacking to
investigate the predominant epitopes recognized by anti-E Abs in
polyclonal sera. Using our approach to examine 14 dengue sera
from secondary infection cases, we demonstrated for the first time
that the predominant epitopes on E protein recognized by
polyclonal sera can be quickly identified. Our findings suggested
that fusion loop residues (such as W101, F108, L107 and G106)
together with some non-fusion loop residues (such as G78, D290 or
T293) in the same or adjacent monomer likely constitute a
predominant epitope in these cases. It is worth noting that the
symmetry of VLPs is not identical to that of virions. Several studies
using conformation-sensitive neutralizing mAbs against TBEV E
protein haveshownthat the structureofEproteinonVLPswasvery
similar to that on virions and that E proteins on both VLPs and
virions displayed closely related changes in conformational and
oligomeric state when exposed to acidic pH [14–16]. Since these
mAbs do not recognize multi-protein spanning or interdimer
epitopes on the surface of virions, the possibility that some anti-E
Abs recognizing such epitopes on virions might be missed by VLP-
capture ELISA can not be completely ruled out, especially when
measuring complex samples such as sera.
Cross-reactivity among different flaviviruses has been an
obstacle for serological diagnosis to distinguish various flaviviral
infections [4,17,20]. Studies introducing mutations to the highly
conserved fusion loop residues (such as G106 and L107) have led
to the development of type-specific serodiagnostic assays for
DENV, JEV and SLEV [17,20]. A better understanding of the
epitopes that contribute to flaviviral cross-reactivity would
facilitate the improvement in flaviviral serodiagnosis and epi-
tope-specific diagnostics. Our analysis suggests that in addition to
fusion loop residues, residues at the domain II central interface
(Q211, D215 and P217), an epitope for GR and some CR mAbs,
may be considered for further reduction of cross-reactivity.
Recent studies of high-resolution structures of flaviviral virions
in the presence or absence of Fab of mAb and the mechanisms
involved in neutralization suggested that flavivirus neutralization is
a multiple-hit phenomenon, in which neutralization occurs only
when the binding of Abs to virions exceeds a stoichiometric
threshold [57–60]. The potency of a neutralizing Ab is determined
by several factors including the affinity of Abs and accessibility of
the epitopes, which were affected by the extent of virion
maturation and conformational change of E protein on the virion
[58,59]. Elucidation of the epitopes recognized by potent anti-
DENV neutralizing mAbs have implication for future strategy of
epitope-based subunit vaccine against DENV.
Our analysis of the epitopes recognized by potent and less potent
neutralizing mAbs revealed multiple overlapping residues in A
strand and BC loop of domain III. However, several potent
neutralizing mAbs recognized more than four residues in A strand
(mAbs DV2-76, DV2-70, DV2-106, DV2-96, 1A1D-2, 1F1 and
E99), BC loop (mAbs E101 and E103), or multiple residues in both
A strand andBCloop (mAbs E90,3H5and6B6-10),suggesting that
increased affinity to these epitope residues may account for the
increased potency [32–34] (Table S1). Other potent neutralizing
mAbs recognized certain residues not found in less potent mAbs
such as C strand/CC9 loop (mAbs DV2-77, DV2-73, DV2-104 and
DV2-87), suggesting unique epitope residues of potent neutralizing
mAbs [34] (Table S1). Notably, comparing the epitopes recognized
by these potent neutralizing mAbs against DENV2 and DENV1
revealed both common and different features (Table 2), suggesting
difference in the epitopic structure between DENV1 and DENV2.
Figure 4 highlighted the locations of epitope residues recognized by
these potent neutralizing mAbs. Detailed analysis of the extent of
conservation of these epitope residues might provide important
information for new strategies to elicit highly TS or CR potent
neutralizing Abs using different immunogens. Moreover, future
studies to delineate the epitopes recognized by human neutralizing
mAbs and neutralizing Absinpolyclonalhuman sera would provide
another piece of critical information for rationale design of subunit
vaccine against DENV and add new insight into our understanding
of protective humoral immune responses against DENV during the
natural course of infection.
Supporting Information
Figure S1 Binding specificity of 12 mouse anti-E mAbs.
Western blot analysis was performed by using cell lysates derived
from C6/36 cells infected with each of the 4 DENV serotypes or
JEV. Lysates of 293T cells transfected with pCB-D1 (D1 tr) were
also included.
(TIF)
Figure S2 Western blot analysis. Cell lysates derived from
293T cells transfected with WT pCB-D1 or each of the 67 alanine-
substitution E mutants were probed with mAbs (A) DEN2-12, (B)
DEN4-4, (C) FL0251 and mixed sera, which consisted of a pool of
9 sera from confirmed dengue patients. R.I. of each mutant was
determined as described in Methods [44,48].
(TIF)
Figure S3 Epitope mapping of TS mAb FL0251. The
results of (A, B, C) dot blot assay, (D) VLP-capture ELISA, and (F)
structure based analysis of the location of and distance (uA)
between epitope residues from the same or adjacent monomer are
presented as in Fig. 2. Arrow heads indicate mutants of epitope
residues, which showed moderate reduction in binding
(0.3,R.I.#0.5) by dot blot and Western blot analyses.
(TIF)
Figure S4 Binding specificity and predominant epitope
recognized by anti-E Abs in human sera from dengue
cases. Shown are cases of DENV2 (A,B,C), and DENV3 (D,E,F).
(A,D) Binding specificity was examined by Western blot analysis as
described in Methods. Lysates of 293T cells transfected with pCB-
D1 (D1 tr) were also included. (B,E) Dot blot assay presented as in
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www.plosntds.org 10 January 2012 | Volume 6 | Issue 1 | e1447Fig. 1A and 1C to 1E (except that WT dot in row 8C and 153NA
dot in row 2H were omitted) was probed with the tested serum or
mixed sera, which consisted of a pool of 9 sera from confirmed
dengue patients [44]. The relative intensities of two-fold dilutions
of WT dots in row 1 were presented as in Fig. 1D. R.I. of each
mutant was shown as in Fig. 1E. One representative experiment of
two was shown. (C,F) Capture ELISA using WT or mutant VLPs
was presented as in Fig. 1F. Upper graph in panel C shows
comparable amounts of WT and mutant VLPs added.
(TIF)
Table S1 Comparison of epitopes, neutralization po-
tency and immunization protocol of CR/sCR and TS
mAbs recognizing domain III of DENV E protein.
(DOC)
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